My guest today is Paul Ward. He is the National Director, Oncology MSLs at AstraZeneca, and MSL Society Advisory Board Member. We will discuss how Covid-19 will affect the role of the MSL and what new skills may emerge as necessary to maintain value, access, and future success.

(0:00) Introduction of Paul Ward and episode focus

(0:41) Paul Ward's background and current role

(2:20) Impact of COVID-19 on MSLs' personal and professional lives

(4:46) MSL responsibilities and HCP interactions during the pandemic

(10:02) Challenges and strategies for virtual MSL engagements

(15:21) Future of virtual interactions in the MSL role

(19:59) Developing skills for effective virtual interactions

(24:00) HCP and patient expectations from MSLs during and post-COVID-19

(26:01) MSL performance metrics and expectations

(28:40) Quantitative vs. qualitative metrics for MSLs

(31:19) Changing patient expectations and healthcare dynamics

(34:21) Advice for MSLs to adapt and add value

(36:25) Impact of COVID-19 on MSL recruitment and hiring

(39:13) Future outlook for MSL roles and medical affairs

(40:11) Closing remarks and subscription reminder